United Therapeutics (UTHR) Short-Term Debt issuances (2014 - 2025)

United Therapeutics (UTHR) has 7 years of Short-Term Debt issuances data on file, last reported at $400.0 million in Q2 2025.

• For the quarter ending Q2 2025, Short-Term Debt issuances rose 500.0% year-over-year to $400.0 million; the trailing twelve-month figure through Mar 2026 stood at $400.0 million (changed N/A YoY), and the FY2025 full-year result was $500.0 million, changed N/A from the prior year.
• Short-Term Debt issuances climbed to $400.0 million in Q2 2025, from $100.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $800.0 million in Q1 2022 to a low of -$100.0 million in Q2 2024.
• A 4-year average of $233.3 million and a median of $100.0 million in 2023 frame the typical range for Short-Term Debt issuances.
• Peak annual rise in Short-Term Debt issuances reached 500.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Tracing UTHR's Short-Term Debt issuances over 4 years: stood at $800.0 million in 2022, then plunged by 87.5% to $100.0 million in 2023, then tumbled by 200.0% to -$100.0 million in 2024, then soared by 500.0% to $400.0 million in 2025.
• Business Quant data shows UTHR's Short-Term Debt issuances at $400.0 million in Q2 2025, $100.0 million in Q1 2025, and -$100.0 million in Q2 2024.